AstraZeneca to stop making Pulmicort inhaler; SkyePharma shares slump
This article was originally published in Scrip
Executive Summary
AstraZeneca's "unexpected" decision to stop manufacturing the Pulmicort (budesonide) pressurised metered dose inhaler (pMDI), for which SkyePharma developed the formulation, does not have any implications for SkyePharma's Flutiform (fluticasone propionate plus formoterol fumarate), which is currently being assessed by European regulators, SkyePharma CFO Peter Grant told Scrip.